I found this article about the SGLT2 inhibitor jardiance EMPA-REG OUTCOME trial to be very informative. BETonMACE will likely have a lot of similarities in the patient recruitment criteria, and will additionally require low-HDL. EMPA-REG OUTCOME results on MACE reduction will be revealed at the mid-September EASD meeting....the same meeting that RVX is talking at. It will be very informative to see the MACE incidence rate in the control and treated patients in the EMPA-REG OUTCOME trial to help put our post-hoc analysis numbers is better perspective.